NSABP近十年乳腺癌临床试验进展

doi:10.3760/cma.j.issn.1673-422X.2017.07.018

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (7): 547-549.doi: 10.3760/cma.j.issn.1673-422X.2017.07.018

NSABP近十年乳腺癌临床试验进展

黄杰峰，林晓榕，吴智勇

515000 汕头市中心医院中山大学附属汕头医院乳腺疾病诊疗中心（黄杰峰、吴智勇）；中山大学孙逸仙纪念医院（林晓榕）

收稿日期:2017-02-13 出版日期:2017-07-08 发布日期:2017-06-20
通讯作者: 吴智勇 E-mail:stwuzy@163.com

Advances of NSABP breast cancer trails in the past decade

Huang Jiefeng, Lin Xiaorong, Wu Zhiyong

Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou Affiliated Hospital of Sun YatSen University, Shantou 515000, China

Received:2017-02-13 Online:2017-07-08 Published:2017-06-20
Contact: Wu Zhiyong E-mail:stwuzy@163.com

摘要/Abstract

摘要： 【摘要】近十年来，美国国家乳腺和肠道外科辅助治疗研究组公布的研究结果继续改变着早期乳腺癌的临床实践：前哨淋巴结活检成为新的外科操作标准，芳香化酶抑制剂辅助内分泌治疗从5年延长到10年可使高危高激素反应人群获益，化疗联合曲妥珠单抗成为人类表皮生长因子受体2阳性浸润性乳腺癌标准辅助治疗策略。此外，其研究进展还涉及术后辅助化疗、新辅助化疗方案优化等领域。

关键词: 乳腺肿瘤, 外科手术, 肿瘤辅助疗法

Abstract: The research findings published by National Surgical Adjuvant Breast and Bowel Project have continued to change the clinical practice of earlystage breast cancer over the past decade. Sentinel lymph node biopsy has become the new surgical operation standard. The aromatase inhibitor adjuvant endocrine therapy cycle has been extended from 5 years to 10 years, which benefits the patients with high risk and reactivity. Chemotherapy combined with trastuzumab has become the standard adjuvant therapy strategy of human epidermal growth factor receptor 2 positive invasive breast cancer. In addition, the research progress is also related to the optimization of the fields including the postoperative adjuvant chemotherapy and neoadjuvant chemotherapy.

Key words: Breast neoplasms, Surgical procedures, Adjuvant therapy

黄杰峰，林晓榕，吴智勇. NSABP近十年乳腺癌临床试验进展[J]. 国际肿瘤学杂志, 2017, 44(7): 547-549.

Huang Jiefeng, Lin Xiaorong, Wu Zhiyong. Advances of NSABP breast cancer trails in the past decade[J]. Journal of International Oncology, 2017, 44(7): 547-549.

参考文献

［1］ Krag DN, Anderson SJ, Julian TB, et al. Sentinellymphnode resection compared with conventional axillarylymphnode dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B32 randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 927-933. DOI: 10.1016/S14702045(10)702072. ［2］ Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer［J］. N Engl J Med, 2010, 362(22): 2053-2065. DOI: 10.1056/NEJMoa0909638. ［3］ Swain SM, Tang G, Geyer CE, et al. Definitive results of a phase Ⅲ adjuvant trial comparing three chemotherapy regimens in women with operable, nodepositive breast cancer: the NSABP B38 trial［J］. J Clin Oncol, 2013, 31(26): 3197-3204. DOI: 10.1200/JCO.2012.48.1275. ［4］ Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intentiontotreat analysis of the National Surgical Adjuvant Breast and Bowel Project B33 trial［J］. J Clin Oncol, 2008, 26(12): 19651971. DOI: 10.1200/JCO.2007.14.0228. ［5］ Mamounas EP, Lembersky B, Jeong J, et al. NSABP B42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging diseasefree survival in postmenopausal women with hormone receptorpositive breast cancer［J］. Clin Breast Cancer, 2006, 7(5): 416421. DOI: 10.3816/CBC.2006.n.061. ［6］ Wapnir IL, Dignam JJ, Fisher B, et al. Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS［J］. J Natl Cancer Inst, 2011, 103(6): 478488. DOI: 10.1093/jnci/djr027. ［7］ Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, doubleblind, phase 3 clinical trial［J］. Lancet, 2016, 387(121): 849-856. DOI: 10.1016/S0140-6736(15)01168-X. ［8］ Siziopikou KP, Anderson SJ, Cobleigh MA, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B43［J］. Breast Cancer Res Treat, 2013, 142(2): 415-421. DOI: 10.1007/s10549-013-2755-z. ［9］ Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831［J］. J Clin Oncol, 2014, 32(33): 3744-3752. DOI: 10.1200/JCO.2014.55.5730. ［10］ Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B40 ［NRG Oncology］): secondary outcomes of a phase 3, randomised controlled trial［J］. Lancet Oncol, 2015, 16(9): 1037-1048. DOI: 10.1016/S1470-2045(15)00041-8. ［11］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer (NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1183-1192. DOI: 10.1016/S1470-2045(13)70411-X.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	杨博, 付茂勇. 单孔胸腔镜下左上肺舌段癌袖式切除同期行右肺上叶癌切除术1例[J]. 国际肿瘤学杂志, 2024, 51(2): 126-128.
[6]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[14]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[15]	赵永瑞, 高莹, 陈怡东, 徐建堃. 基于直线加速器的分次立体定向放疗对小体积脑转移瘤的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 138-143.

NSABP近十年乳腺癌临床试验进展

Advances of NSABP breast cancer trails in the past decade

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价